DE69830582D1 - Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind - Google Patents

Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Info

Publication number
DE69830582D1
DE69830582D1 DE69830582T DE69830582T DE69830582D1 DE 69830582 D1 DE69830582 D1 DE 69830582D1 DE 69830582 T DE69830582 T DE 69830582T DE 69830582 T DE69830582 T DE 69830582T DE 69830582 D1 DE69830582 D1 DE 69830582D1
Authority
DE
Germany
Prior art keywords
lactoferrine
allergens
treatment
complaints caused
complaints
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830582T
Other languages
English (en)
Other versions
DE69830582T2 (de
Inventor
Ian Kimber
Marie Cumberbatch
J Dearman
M Conneely
Pauline Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Application granted granted Critical
Publication of DE69830582D1 publication Critical patent/DE69830582D1/de
Publication of DE69830582T2 publication Critical patent/DE69830582T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69830582T 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind Expired - Lifetime DE69830582T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
US41890P 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (2)

Publication Number Publication Date
DE69830582D1 true DE69830582D1 (de) 2005-07-21
DE69830582T2 DE69830582T2 (de) 2006-05-04

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830582T Expired - Lifetime DE69830582T2 (de) 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Country Status (12)

Country Link
US (1) US20030190303A1 (de)
EP (1) EP0979099B1 (de)
JP (1) JP2001519815A (de)
CN (1) CN1262625A (de)
AT (1) ATE297755T1 (de)
AU (1) AU747385C (de)
CA (1) CA2285960A1 (de)
DE (1) DE69830582T2 (de)
ES (1) ES2245028T3 (de)
IL (1) IL132293A0 (de)
NZ (1) NZ500712A (de)
WO (1) WO1998044940A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7368198A (en) * 1997-05-03 1998-11-27 Board Of Regents, The University Of Texas System Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN1205998C (zh) * 2000-01-14 2005-06-15 明治乳业株式会社 抗原特异性IgE抗体产生抑制剂
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
AU2002359949A1 (en) * 2001-12-28 2003-07-24 Nrl Pharma, Inc. Compositions for improving lipid metabolism
EP2543385A1 (de) 2002-01-21 2013-01-09 NRL Pharma, Inc. Neuartige Analgetika
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US7238661B2 (en) 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
EA033750B1 (ru) 2002-09-06 2019-11-21 Amgen Inc Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
JP4516844B2 (ja) 2002-09-16 2010-08-04 エイジェニックス インコーポレイテッド 創傷の処置におけるラクトフェリン
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
CA2527904A1 (en) 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
JP2008501772A (ja) * 2004-06-11 2008-01-24 シンジェンタ リミテッド 炎症性皮膚状態を寛解するための方法
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
KR101242428B1 (ko) * 2005-03-15 2013-03-12 캄피나 네덜란드 홀딩 베.붸. 유즙 단백질의 피부학적 용도
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
EP1937298A4 (de) * 2005-10-14 2009-11-11 Auckland Uniservices Ltd Verwendung von lactoferrin-fragmenten und hydrolysaten
EP1952818A4 (de) * 2005-10-27 2009-10-21 Sunstar Inc Hemmer der osteoklastenbildung, zusammensetzung zur oralen verabreichung und prophylaktisches oder therapeutisches mittel gegen knochenkrankheiten mit lactoferrin-haltigem liposom
EP2560679A4 (de) * 2010-04-23 2013-09-18 Probiotec Ltd Behandlung von ekzemen
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
EP3836954A1 (de) 2018-08-13 2021-06-23 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
EP4072322A1 (de) * 2019-12-11 2022-10-19 N.V. Nutricia Nährstoffzusammensetzung zur verbesserung der immunfitness
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof

Also Published As

Publication number Publication date
IL132293A0 (en) 2001-03-19
DE69830582T2 (de) 2006-05-04
EP0979099B1 (de) 2005-06-15
AU6964798A (en) 1998-10-30
JP2001519815A (ja) 2001-10-23
CA2285960A1 (en) 1998-10-15
NZ500712A (en) 2002-10-25
EP0979099A1 (de) 2000-02-16
AU747385B2 (en) 2002-05-16
WO1998044940A1 (en) 1998-10-15
CN1262625A (zh) 2000-08-09
AU747385C (en) 2003-01-30
ES2245028T3 (es) 2005-12-16
US20030190303A1 (en) 2003-10-09
ATE297755T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
DE69830582D1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE296799T1 (de) P38-inhibitoren
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
DK0841898T3 (da) Topiske sammensætninger, der har forbedret hudfornemmelse
BR0007556A (pt) Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
DE69729796D1 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
DE69829866D1 (de) Sklerotische prothese für die behandlung von altersweitsichtigkeit und anderen augenkrankheiten
MY117696A (en) INHIBITORS OF p38
BRPI0411784A (pt) anticorpos contra interleucina -22 e usos para os mesmos
FI935585A0 (fi) Pyrrolopyrimidiner
DE60238149D1 (de) Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen
DE69316948D1 (de) Lösliche Liganden für CD40
BG103575A (en) SUBSTITUTED NITROGENCONTAINING HETEROCYCLES AS p38 PROTEINKINASE INHIBIRORS
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
NO20000396D0 (no) Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
DE60005953D1 (de) Stapelbare statische mischelemente
DE60034155D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
ATE249835T1 (de) Immunoregulator
DE59909607D1 (de) Tan-1057 derivate
DK0506836T3 (da) BCRF1 proteiner som inhibitorer for interferon-gamma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition